New drug duo aims to tackle stubborn breast cancer before surgery

NCT ID NCT05675579

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving sacituzumab govitecan and pembrolizumab before surgery can help control early-stage triple-negative breast cancer that didn't respond to initial chemotherapy and immunotherapy. The study enrolls 27 adults with specific tumor types. The main goal is to check safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan and pembrolizumab (given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with early-stage triple-negative breast cancer that hasn't responded to standard chemotherapy and immunotherapy.
What could go wrong: This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination may cause side effects and may not improve outcomes enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.